Loading...
Several published case reports have described patients developing cutaneous or ophthalmic zoster immediately after receipt of the recombinant herpes zoster vaccine (Shingrix, GSK). To assess the significance of these observations, researchers analyzed two large clinical databases in Australia — one comprising about 12 million outpatient records and the other consisting of emergency department (ED) and hospital-based records from the Melbourne area.
People ≥65 years of age in the outpatient database were 10 times more likely to be diagnosed with zoster in the 3 weeks after their first dose of recombinant vaccine than in the year before vaccination. A much smaller excess risk was seen during the subsequent periods leading up …
